Updates on Targeted Therapy for Triple-Negative Breast Cancer (TNBC)
| Autor: | Zorawar S. Noor, Aashini K. Master |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Chemotherapy Standard of care Platinum Agents business.industry medicine.medical_treatment medicine.disease Targeted therapy 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Breast cancer Surgical oncology Novel agents 030220 oncology & carcinogenesis Internal medicine medicine business Triple-negative breast cancer |
| Zdroj: | Current Breast Cancer Reports. 10:282-288 |
| ISSN: | 1943-4596 1943-4588 |
| DOI: | 10.1007/s12609-018-0291-x |
| Popis: | We will provide a brief update of the most recent advances in targeted therapies for triple-negative breast cancer (TNBC) to help guide the practicing oncologist faced with the dilemma of how to treat this complex disease. The current standard of care remains chemotherapy, with recent data supporting the use of platinum agents and poly(ADP-ribose) polymerases (PARP) inhibitors. Immune checkpoint inhibitor trials have also shown efficacy. TNBCs are grouped together, yet there is an extraordinary amount of diversity amongst these cancers, which have distinct molecular subtypes that predict response to therapy. The use of platinum agents and PARP inhibitors is now well supported. Novel agents including checkpoint inhibitors and antibody-drug conjugates hold promising avenues for the future. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink